Seoul National University Prospectively Enrolled Registry for Prostate Cancer With Active Surveillance
Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Nov 18, 2016
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, based at Seoul National University, is focused on studying how prostate cancer can be monitored without immediate treatment, a method known as active surveillance. Researchers want to understand how many men experience changes in their cancer status over five years while being closely monitored. This study is currently recruiting male participants who are under 80 years old and have been diagnosed with a specific type of prostate cancer based on a biopsy.
To be eligible for this trial, men must have a certain level of prostate-specific antigen (PSA) and meet other criteria related to their cancer's characteristics. Participants will need to commit to regular follow-up visits to check on their condition over time. This trial is important for improving how we manage prostate cancer in men who may not need immediate treatment, allowing for better, more personalized care.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Men \< 80 years
- • 2. Pathologically proven adenocarcinoma of the prostate by transrectal prostate biopsy ≥ 10 cores
- • 3. Pre-Bx PSA ≤ 10ng/ml
- • 4. PSA density \< 0.15ng/ml/ml
- • 5. Clinical stage T1-2a
- • 6. Biopsy Gleason score ≤ 6
- • 7. No. of positive cores ≤ 2
- • 8. Maximum cancer involvement in any one core ≤ 20%.
- • 9. No PIRADS 5 lesion on multiparametric prostate MRI (1.5T or 3T)
- • 10. Participants must be willing to attend the follow-up visits - T1a-b disease should be confirmed by systematic TRUS-Bx ≥ 10 cores
- Exclusion Criteria:
- • 1. A former therapy for prostate cancer.
About Seoul National University Hospital
Seoul National University Hospital (SNUH) is a leading medical institution in South Korea, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SNUH integrates cutting-edge scientific inquiry with patient-centered care, facilitating the development of novel therapies and treatment protocols. The hospital boasts a diverse range of specialized departments and a robust infrastructure for conducting clinical studies, ensuring rigorous adherence to ethical standards and regulatory compliance. By fostering collaboration among multidisciplinary teams, SNUH aims to contribute significantly to global medical advancements and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
Chang Wook Jeong, M.D, Ph.D
Principal Investigator
Seoul National University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials